Monoclonal fluorescence polarization immunoassay evaluated for monitoring cyclosporine in whole blood after kidney, heart, and liver transplantation.
In a prospective study we evaluated a novel fluorescence polarization immunoassay (FPIA) for determining cyclosporine (CsA) in whole blood. FPIA uses a monoclonal antibody and is performed on the TDx (Abbott). The within-series (CV less than 2%) and between-days (CV less than 3.3%) precision of the assay was excellent. The results obtained by the monoclonal FPIA in samples from transplant patients (n = 100) averaged 31.9% and 20.2% higher than those by HPLC and a specific radioimmunoassay (INCStar), respectively. Results by all three methods correlated well. Follow-up studies during the early course after liver transplantation, however, suggested that high metabolite concentrations affect FPIA results. This is explained by previously described cross-reactions of the monoclonal antibody with some CsA metabolites. The FPIA results in samples of such patients should be interpreted cautiously.
Winkler
M
M
Klinik für Abdominal und Transplantationschirurgie, Medizinische Hochschule Hannover, F.R.G.
Schumann
G
G
Petersen
D
D
Oellerich
M
M
Wonigeit
K
K
D002851:Chromatography, High Pressure Liquid; D016572:Cyclosporine / Q000097:blood*; D016231:Fluorescence Polarization Immunoassay / Q000592:standards / Q000706:statistics & numerical data; D005500:Follow-Up Studies; D016027:Heart Transplantation; D006801:Humans; D016030:Kidney Transplantation; D016031:Liver Transplantation; D011446:Prospective Studies; D011863:Radioimmunoassay
D016572:Cyclosporine